SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 786.65 |
| Enterprise Value ($M) | 846.18 |
| Book Value ($M) | 311.74 |
| Book Value / Share | 6.36 |
| Price / Book | 2.52 |
| NCAV ($M) | 72.74 |
| NCAV / Share | 1.48 |
| Price / NCAV | 10.81 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.53 |
| Return on Assets (ROA) | -0.35 |
| Return on Equity (ROE) | -0.57 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.57 |
| Current Ratio | 2.57 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 334.97 |
| Assets | 573.97 |
| Liabilities | 262.23 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 90.24 |
| Operating Income | -264.43 |
| Net Income | -263.49 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -218.41 |
| Cash from Investing | 190.94 |
| Cash from Financing | -34.97 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Redmile Group, LLC | 8.60 | -11.27 | |
| 13G/A | Vanguard Group Inc | 10.09 | 1.80 | |
| 13G/A | GIC Private Ltd | 2.37 | -52.60 | |
| 13G/A | Jpmorgan Chase & Co | 8.90 | 3.63 | |
| 13G/A | State Street Corp | 5.98 | -3.13 | |
| 13G/A | BlackRock Inc. | 18.70 | 22.75 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 145,101 | 255,270 | 56.84 | |
| 50,112 | 152,575 | 32.84 | |
| 51,725 | 148,688 | 34.79 | |
| 37,886 | 167,615 | 22.60 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| REGN – Regeneron Pharmaceuticals, Inc. | REPL – Replimune Group, Inc. |
| RGEN – Repligen Corporation | RIGL – Rigel Pharmaceuticals, Inc. |
| RLMD – Relmada Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io